Publicaciones en las que colabora con VICENTE JOSE BODI PERIS (212)

2024

  1. Combining loop with thiazide diuretics in patients discharged home after a heart failure decompensation: Association with 30-day outcomes

    European Journal of Internal Medicine

  2. Differential sex-related effect of left ventricular ejection fraction trajectory on the risk of mortality and heart failure readmission following hospitalization for acute heart failure: A longitudinal study

    European Journal of Heart Failure

  3. Impact of Epicardial Adipose Tissue on Infarct Size and Left Ventricular Systolic Function in Patients with Anterior ST-Segment Elevation Myocardial Infarction

    Diagnostics, Vol. 14, Núm. 4

  4. Short-Course High-Intensity Statin Treatment during Admission for Myocardial Infarction and LDL-Cholesterol Reduction—Impact on Tailored Lipid-Lowering Therapy at Discharge

    Journal of Clinical Medicine, Vol. 13, Núm. 1

  5. β-Blocker Withdrawal and Functional Capacity Improvement in Patients with Heart Failure with Preserved Ejection Fraction

    JAMA Cardiology, Vol. 9, Núm. 4, pp. 392-396

2023

  1. Chronotropic index and long-term outcomes in heart failure with preserved ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 511-518

  2. Clinical Predictors and Prognosis of Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA) without ST-Segment Elevation in Older Adults

    Journal of Clinical Medicine, Vol. 12, Núm. 3

  3. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  4. Early glomerular filtration rates changes and risk of mortality in acute heart failure. The modifying role of admission renal function and decongestion

    European Journal of Internal Medicine, Vol. 115, pp. 96-103

  5. Eficacia de la realidad virtual en la reducción de la ansiedad en la revascularización de las OTC: diseño del ensayo ReViCTO

    REC: Interventional Cardiology, Vol. 5, Núm. 3, pp. 203-209

  6. Risk of death associated with incident heart failure in patients with known or suspected chronic coronary syndrome

    ESC Heart Failure, Vol. 10, Núm. 1, pp. 264-273

  7. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

    JACC: Heart Failure, Vol. 11, Núm. 11, pp. 1611-1622

2022

  1. Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure

    European Journal of Heart Failure, Vol. 24, Núm. 11, pp. 2108-2117

  2. Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction

    Scientific Reports, Vol. 12, Núm. 1

  3. Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis

    Journal of Clinical Medicine, Vol. 11, Núm. 9

  4. Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure

    Revista Espanola de Cardiologia, Vol. 75, Núm. 4, pp. 316-324

  5. Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure

    European Journal of Internal Medicine, Vol. 95, pp. 67-73

  6. Short-Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial-IRON Trial

    Journal of the American Heart Association, Vol. 11, Núm. 7, pp. e022214

  7. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 10, pp. 1816-1826

2021

  1. Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review

    European Journal of Heart Failure, Vol. 23, Núm. 9, pp. 1445-1457